{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:25Z","timestamp":1785484705246,"version":"3.56.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We present a case of emergent integrase strand transfer inhibitor resistance following rifamycin-based latent tuberculosis infection (LTBI) treatment in a patient with HIV-1This case highlights the risks associated with modifying antiretroviral therapy during LTBI treatment and illustrates how archived genotype results can directly impact clinical decision-making.<\/jats:p>","DOI":"10.1093\/ofid\/ofag448","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T11:33:26Z","timestamp":1784460806000},"source":"Crossref","is-referenced-by-count":0,"title":["Emergence of Integrase Strand Transfer Inhibitor Resistance Following Treatment of Latent Tuberculosis Infection in a Patient With HIV"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5660-9652","authenticated-orcid":false,"given":"Emily","family":"Dyer","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3068-3732","authenticated-orcid":false,"given":"Shawnalyn W","family":"Sunagawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Nebraska Medical Center, College of Pharmacy , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2760-7936","authenticated-orcid":false,"given":"Nichole","family":"Regan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-1490","authenticated-orcid":false,"given":"Jennifer M","family":"Davis","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-2505","authenticated-orcid":false,"given":"Sara H","family":"Bares","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska Medical Center, College of Medicine , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2026073103113034900_ofag448-B1"},{"key":"2026073103113034900_ofag448-B2","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1097\/QAD.0000000000003645","article-title":"Updated mortality and causes of death in 2020-2021 in people with HIV: a multicenter study in France","volume":"37","author":"Sellier","year":"2023","journal-title":"AIDS"},{"key":"2026073103113034900_ofag448-B3","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMcp2108501","article-title":"Latent tuberculosis infection","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"key":"2026073103113034900_ofag448-B4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","author":"Smith","year":"2014","journal-title":"Lancet"},{"key":"2026073103113034900_ofag448-B5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciae014","article-title":"Time trends in causes of death in people with HIV: insights from the Swiss HIV cohort study","volume":"79","author":"Weber","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026073103113034900_ofag448-B6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13318-023-00833-9","article-title":"Management of drug interactions with inducers: onset and disappearance of induction on cytochrome P450 3A4 and uridine diphosphate glucuronosyltransferase 1A1 substrates","volume":"48","author":"Bettonte","year":"2023","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2026073103113034900_ofag448-B7","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bcp.15604","article-title":"Drug-drug interaction between rifabutin and dolutegravir: a population pharmacokinetic model","volume":"89","author":"Kawuma","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"2026073103113034900_ofag448-B8","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2025"},{"key":"2026073103113034900_ofag448-B9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026073103113034900_ofag448-B10","doi-asserted-by":"crossref","first-page":"e1677","DOI":"10.1097\/MD.0000000000001677","article-title":"Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens","volume":"94","author":"Clay","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2026073103113034900_ofag448-B11","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials","volume":"58","author":"Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026073103113034900_ofag448-B12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2016.04.082","article-title":"Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis","volume":"216","author":"Weeda","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026073103113034900_ofag448-B13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"2026073103113034900_ofag448-B14","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/v15091932","article-title":"Treatment emergent dolutegravir resistance mutations in individuals naive to HIV-1 integrase inhibitors: a rapid scoping review","volume":"15","author":"Tao","year":"2023","journal-title":"Viruses"},{"key":"2026073103113034900_ofag448-B15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2026073103113034900_ofag448-B16","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/ciaf161","article-title":"Utilizing HIV proviral DNA to assess for the presence of HIV drug resistance","volume":"81","author":"Wensing","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026073103113034900_ofag448-B17","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1128\/AAC.00292-13","article-title":"Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans","volume":"57","author":"Castellino","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026073103113034900_ofag448-B18","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/jcph.70061","article-title":"Clinical evaluation of drug-drug interactions between bictegravir and strong inhibitors\/inducers of the CYP3A4, UGT1A1, or P-gp pathways","volume":"65","author":"Arora","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"2026073103113034900_ofag448-B19","doi-asserted-by":"crossref","first-page":"ofz533","DOI":"10.1093\/ofid\/ofz533","article-title":"Clinical outcomes following the use of archived proviral HIV-1 DNA genotype to guide antiretroviral therapy adjustment","volume":"7","author":"Ellis","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026073103113034900_ofag448-B20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/cid\/ciae475","article-title":"Virological history predicts non-sustained viral suppression with long-acting cabotegravir and rilpivirine therapy, independent of pharmacokinetic parameters","volume":"80","author":"Guti\u00e9rrez","year":"2025","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag448\/69762967\/ofag448.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag448\/69762967\/ofag448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/7\/ofag448\/69762967\/ofag448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:11:43Z","timestamp":1785481903000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag448\/8739566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag448","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"ofag448"}}